Insilico Medicine, a Hong Kong-based start-up specialized in next-generation artificial intelligence (AI) technology for drug discovery, has raised US$37 million in a series B round of financing led by Chinese venture capital firm Qiming Venture Partners, according to a statement released on Tuesday.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
